Difference in toxicity between HIV-positive and HIV-negative patients with squamous-cell cancer of the anal canal treated with concomitant radio-chemotherapy.
HIV
anal canal cancer (ACC)
radio-chemotherapy (RTCT)
Journal
Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
entrez:
17
3
2020
pubmed:
17
3
2020
medline:
17
3
2020
Statut:
ppublish
Résumé
The incidence of squamous cell carcinoma of the anal canal has been increasing over the last 30 years. HIV has been found to be a risk factor for the development of this disease; radio-chemotherapy (RTCT) may also be more toxic than in HIV-negative patients. The study aims at assessing whether there are any differences in terms of toxicity between HIV-positive and HIV-negative patients treated with concomitant RTCT. Search in MEDLINE, EMBASE, CENTRAL (via Cochrane Library-Wiley), DARE, LILACS bibliographic databases. Experimental and analytical observational studies with at least two comparative arms were included: squamous-cell (SC) anal-canal cancer (ACC) treated with RTCT in HIV-positive Fifteen publications, 14 retrospective studies and 1 systematic review, were found. All radiotherapy (RT) techniques and all chemotherapeutic agents used to manage this disease were included. No differences were found in terms of duration (P=0.67) and dose (P=0.53) of RT, while CT results were contradictory. Acute and hematological toxicities were significantly higher in HIV-positive patients, while gastrointestinal, dermatological and chronic toxicities did not significantly differ between the two groups. Given the high heterogeneity of the studies, no objective comparison could be made between studies that included antiretrovirals and those that did not. HIV-positive patients may be at higher risk for acute and hematological toxicity than HIV-negative patients. A precise conclusion cannot be drawn on the use of antiretrovirals, given the high heterogeneity of data.
Sections du résumé
BACKGROUND
BACKGROUND
The incidence of squamous cell carcinoma of the anal canal has been increasing over the last 30 years. HIV has been found to be a risk factor for the development of this disease; radio-chemotherapy (RTCT) may also be more toxic than in HIV-negative patients. The study aims at assessing whether there are any differences in terms of toxicity between HIV-positive and HIV-negative patients treated with concomitant RTCT.
METHODS
METHODS
Search in MEDLINE, EMBASE, CENTRAL (via Cochrane Library-Wiley), DARE, LILACS bibliographic databases. Experimental and analytical observational studies with at least two comparative arms were included: squamous-cell (SC) anal-canal cancer (ACC) treated with RTCT in HIV-positive
RESULTS
RESULTS
Fifteen publications, 14 retrospective studies and 1 systematic review, were found. All radiotherapy (RT) techniques and all chemotherapeutic agents used to manage this disease were included. No differences were found in terms of duration (P=0.67) and dose (P=0.53) of RT, while CT results were contradictory. Acute and hematological toxicities were significantly higher in HIV-positive patients, while gastrointestinal, dermatological and chronic toxicities did not significantly differ between the two groups. Given the high heterogeneity of the studies, no objective comparison could be made between studies that included antiretrovirals and those that did not.
CONCLUSIONS
CONCLUSIONS
HIV-positive patients may be at higher risk for acute and hematological toxicity than HIV-negative patients. A precise conclusion cannot be drawn on the use of antiretrovirals, given the high heterogeneity of data.
Identifiants
pubmed: 32175102
doi: 10.21037/jgo.2020.01.05
pii: jgo-11-01-23
pmc: PMC7052764
doi:
Types de publication
Journal Article
Langues
eng
Pagination
23-35Informations de copyright
2020 Journal of Gastrointestinal Oncology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
J Gastrointest Oncol. 2019 Feb;10(1):48-60
pubmed: 30788159
Dis Colon Rectum. 2011 Jun;54(6):729-35
pubmed: 21552058
Clin Oncol (R Coll Radiol). 2017 Apr;29(4):248-255
pubmed: 28049602
Dis Colon Rectum. 2001 Oct;44(10):1496-502
pubmed: 11598480
J Clin Oncol. 1996 Sep;14(9):2527-39
pubmed: 8823332
Radiat Oncol. 2006 Aug 18;1:29
pubmed: 16916475
Am J Clin Oncol. 2017 Aug;40(4):386-392
pubmed: 25513996
Eur J Cancer. 2000 Apr;36(6):754-8
pubmed: 10762748
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Dis Colon Rectum. 2015 Dec;58(12):1130-6
pubmed: 26544809
J Clin Oncol. 2008 May 20;26(15):2550-7
pubmed: 18427149
Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5
pubmed: 9169819
Aliment Pharmacol Ther. 2009 Aug 15;30(4):414-21
pubmed: 19392867
J Clin Oncol. 2012 Dec 10;30(35):4344-51
pubmed: 23150707
Dis Colon Rectum. 2009 May;52(5):891-7
pubmed: 19502853
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):143-9
pubmed: 19203845
J Natl Compr Canc Netw. 2018 Jul;16(7):903-908
pubmed: 30006430
J Clin Oncol. 2008 Jan 20;26(3):474-9
pubmed: 18202423
Lancet. 1996 Oct 19;348(9034):1049-54
pubmed: 8874455
Radiology. 1994 Oct;193(1):251-4
pubmed: 8090901
Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):206-11
pubmed: 16904522
Cancer. 1997 Aug 15;80(4):805-15
pubmed: 9264365
Dis Colon Rectum. 2008 Jan;51(1):73-81
pubmed: 18066626
Gastroenterol Clin Biol. 2002 Feb;26(2):150-6
pubmed: 11938066
Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31
pubmed: 10219805
Arch Intern Med. 2010 Aug 9;170(15):1337-45
pubmed: 20696958
Radiother Oncol. 2011 Jan;98(1):99-104
pubmed: 21168927
Am J Clin Oncol. 2011 Apr;34(2):135-9
pubmed: 20523206
AIDS. 1994 Mar;8(3):283-95
pubmed: 8031509
Hematol Oncol Clin North Am. 2003 Jun;17(3):859-72
pubmed: 12852659
Dis Colon Rectum. 2001 Apr;44(4):506-12
pubmed: 11330577
JAMA. 2008 Apr 23;299(16):1914-21
pubmed: 18430910
J Clin Oncol. 1997 May;15(5):2040-9
pubmed: 9164216
Dis Colon Rectum. 2004 Aug;47(8):1305-9
pubmed: 15484343
Br J Cancer. 2010 Mar 30;102(7):1123-8
pubmed: 20354531
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Radiat Biol. 1995 Oct;68(4):411-2
pubmed: 7594966
Am J Surg. 2016 May;211(5):886-93
pubmed: 26988618